In honor of Ophthalmology Times’ 50th anniversary, we asked a panel of leading ophthalmologists and optometrists across ...

ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

New ISO standards categorize SVIOLs into multifocal, EDOF, and FVR IOLs, requiring rigorous clinical testing for ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Biocon Biologics and Regeneron Pharmaceuticals settled to commercialize aflibercept-jbvf in the US, resolving patent ...